Immune modulation and the role of innate immune cells in allergy and asthma

M. Shamji, R. Boyle
{"title":"Immune modulation and the role of innate immune cells in allergy and asthma","authors":"M. Shamji, R. Boyle","doi":"10.1111/cea.14132","DOIUrl":null,"url":null,"abstract":"Peanut allergy is the most common foodrelated source of an anaphylactic reaction.1 Prevalence of peanut allergy varies considerably by region, but in some highincome countries an estimated 0.2%– 2.5% of children are affected.2 Many studies are exploring potential peanutspecific immunotherapy approaches and one oral immunotherapy treatment has been FDA approved for treatment. To address the need for more effective peanut allergy treatments, Angelina et al.3 investigated the immunomodulation properties of the nonspecific, synthetic cannabinoid molecule, WIN552122, on peanutstimulated dendritic cells (DCs). Human monocytederived dendritic cells (hmoDCs) from healthy donors were stimulated with crude peanut extract (CPE) alone or WIN552122. CPEstimulated hmoDCs activated T cells that produce significantly higher levels of IL5 compared to unstimulated hmoDCs, with no significant changes in IFNγ and IL10. Interestingly, in the presence of WIN552122, T cells secreted significantly lower levels of IFNγ and IL5 and considerably higher levels of IL10 (Figure 1). Additionally, a preclinical model of peanutallergic sensitization was used to assess the ability of WIN552122 to impair peanutinduced DC migration from skin to lymph nodes. BALB/c mice were subjected to CPE sensitization for 3 days with the presence or absence of WIN552122, followed by characterizing the frequency and activation status of DCs in draining lymph nodes. The presence of WIN552122 along CPE sensitization showed a reduction in the migration of DCs to the lymph node and significantly lower numbers of mature DCs. The study findings confirm that WIN552122 shifts the peanutstimulated human DCs from proallergic to tolerogenic responses. It also showed that it is achieved by polarizing TH2 response while increasing IL10 producing CD4+ T cells and FOXP3+ Treg cells. These novel findings may facilitate the development of future novel therapeutic and prophylactic approaches for peanut allergy. Viral respiratory infections, particularly rhinoviruses, are the most prominent trigger of asthma exacerbations.4 Rhinoviruses were shown to induce airway inflammation and worsen clinical symptoms, with increased exacerbation risk for viral infection concurring with allergen exposure for asthmatic patients.5 Although the role of DCs is well established in both viral infections and allergens,6 little is known about their role in viral asthma exacerbations. Cameron et al.7 address this issue by characterizing DC populations in lower airways in moderately severe asthmatic patients in healthy controls. The asthmatic subjects and healthy controls were infected with the rhinovirus (RVA16), with both groups underwent bronchoscopies and bronchoalveolar lavage at baseline (day14), day 3 and day 8 postinfection. The main observation was that at the lower airways,","PeriodicalId":10148,"journal":{"name":"Clinical & Experimental Allergy","volume":"7 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Experimental Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/cea.14132","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Peanut allergy is the most common foodrelated source of an anaphylactic reaction.1 Prevalence of peanut allergy varies considerably by region, but in some highincome countries an estimated 0.2%– 2.5% of children are affected.2 Many studies are exploring potential peanutspecific immunotherapy approaches and one oral immunotherapy treatment has been FDA approved for treatment. To address the need for more effective peanut allergy treatments, Angelina et al.3 investigated the immunomodulation properties of the nonspecific, synthetic cannabinoid molecule, WIN552122, on peanutstimulated dendritic cells (DCs). Human monocytederived dendritic cells (hmoDCs) from healthy donors were stimulated with crude peanut extract (CPE) alone or WIN552122. CPEstimulated hmoDCs activated T cells that produce significantly higher levels of IL5 compared to unstimulated hmoDCs, with no significant changes in IFNγ and IL10. Interestingly, in the presence of WIN552122, T cells secreted significantly lower levels of IFNγ and IL5 and considerably higher levels of IL10 (Figure 1). Additionally, a preclinical model of peanutallergic sensitization was used to assess the ability of WIN552122 to impair peanutinduced DC migration from skin to lymph nodes. BALB/c mice were subjected to CPE sensitization for 3 days with the presence or absence of WIN552122, followed by characterizing the frequency and activation status of DCs in draining lymph nodes. The presence of WIN552122 along CPE sensitization showed a reduction in the migration of DCs to the lymph node and significantly lower numbers of mature DCs. The study findings confirm that WIN552122 shifts the peanutstimulated human DCs from proallergic to tolerogenic responses. It also showed that it is achieved by polarizing TH2 response while increasing IL10 producing CD4+ T cells and FOXP3+ Treg cells. These novel findings may facilitate the development of future novel therapeutic and prophylactic approaches for peanut allergy. Viral respiratory infections, particularly rhinoviruses, are the most prominent trigger of asthma exacerbations.4 Rhinoviruses were shown to induce airway inflammation and worsen clinical symptoms, with increased exacerbation risk for viral infection concurring with allergen exposure for asthmatic patients.5 Although the role of DCs is well established in both viral infections and allergens,6 little is known about their role in viral asthma exacerbations. Cameron et al.7 address this issue by characterizing DC populations in lower airways in moderately severe asthmatic patients in healthy controls. The asthmatic subjects and healthy controls were infected with the rhinovirus (RVA16), with both groups underwent bronchoscopies and bronchoalveolar lavage at baseline (day14), day 3 and day 8 postinfection. The main observation was that at the lower airways,
免疫调节和先天免疫细胞在过敏和哮喘中的作用
花生过敏是最常见的与食物有关的过敏反应来源花生过敏的患病率因地区而异,但在一些高收入国家,估计有0.2% - 2.5%的儿童受到影响许多研究正在探索潜在的花生特异性免疫治疗方法,一种口服免疫治疗方法已被FDA批准用于治疗。为了寻找更有效的花生过敏治疗方法,Angelina等人研究了非特异性合成大麻素分子WIN552122对花生刺激的树突状细胞(dc)的免疫调节特性。用单独的粗花生提取物(CPE)或WIN552122刺激健康供体的人单核细胞来源的树突状细胞(hmoDCs)。与未刺激的hmoDCs相比,cp刺激的hmoDCs激活的T细胞产生了显著更高水平的IL5,而IFNγ和IL10没有显著变化。有趣的是,在WIN552122存在的情况下,T细胞分泌的IFNγ和IL5水平显著降低,而IL10水平显著升高(图1)。此外,一个花生过敏致敏的临床前模型被用来评估WIN552122损害花生诱导的DC从皮肤到淋巴结迁移的能力。在WIN552122存在或不存在的情况下,对BALB/c小鼠进行CPE致敏3天,然后对引流淋巴结中dc的频率和激活状态进行表征。在CPE致敏过程中,WIN552122的存在减少了dc向淋巴结的迁移,并显著降低了成熟dc的数量。研究结果证实,WIN552122将花生刺激的人类dc从原过敏反应转变为耐受性反应。它还表明,这是通过极化TH2反应,同时增加IL10产生CD4+ T细胞和FOXP3+ Treg细胞来实现的。这些新发现可能有助于未来花生过敏的新治疗和预防方法的发展。病毒性呼吸道感染,尤其是鼻病毒,是哮喘加重的最主要诱因鼻病毒可诱发气道炎症,加重临床症状,哮喘患者暴露于过敏原时,病毒感染的加重风险增加虽然dc在病毒感染和过敏原中的作用已得到证实,但它们在病毒性哮喘加重中的作用尚不清楚。Cameron等人7通过对健康对照中重度哮喘患者下气道DC人群进行特征分析,解决了这一问题。哮喘组和健康对照组分别感染鼻病毒(RVA16),两组均在感染后基线(第14天)、第3天和第8天进行支气管镜检查和支气管肺泡灌洗。主要的观察结果是在下呼吸道,
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信